VEGF-silencing siRNAs (Alnylam Pharmaceuticals/Merck)

N/A

Report date: 2022/02/18 13:41:30

Base Information

Drug NameVEGF-silencing siRNAs (Alnylam Pharmaceuticals/Merck)
Drug Alias NameALN-VEG01
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionVascular endothelial growth factor inhibitors
TargetsVascular endothelial growth factor
Therapy Area/IndicationsMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlnylam Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsMacular Degeneration

Other Information

ATC CodeN/A
Related LinksN/A